1 / 63

Enhancing Aspirin Adherence in Cardiovascular Disease Management

Explore issues of underutilization and non-compliance with Aspirin therapy in cardiovascular disease, addressing consequences and strategies for improvement. Learn from global studies and key insights for optimizing patient outcomes.

teva
Télécharger la présentation

Enhancing Aspirin Adherence in Cardiovascular Disease Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bringing Science to Practice: Therapy Underutilization and Compliance in CV disease - The Aspirin Perspective Aspirin underuse, poor compliance and cessationGiuseppe Biondi-Zoccai, MDSapienza University of Rome, Latina, ItalyMelbourne, May 6, 2014 – 16:00 to 19:00 - Room M14, Crown Promenade

  2. Goalsof the Roundtable • Prevalence of non-adherence to Aspirin • Consequences of non-compliance/discontinuation to Aspirin • Issues surrounding non-compliance to Aspirin • Tools and programs to improve compliance to Aspirin

  3. Toooldtobegood?

  4. Toogoodtobetrue?

  5. Do westillneed Aspirin?

  6. What are the facts?

  7. Goalsof the Presentation • Underutilisation and poor adherence in secondary prevention of CVD • Physician and patient perceptions about Aspirin • Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

  8. Updatedterminology • Cessation: anyceasing or discontinuance • Compliance: accuracy with which a patient follows an agreed treatment plan • Discontinuation: physician-supervised withdrawal as perceived as no longer needed • Disruption: cessation due to non-compliance or bleeding (brief: 1-5 days; temporary: 6-30 days; permanent: >30 days) • Interruption: physician-supervised temporary discontinuation for surgery lasting <15 days • Underuse: act of using (or prescribing) less than expected Mehranet al, Lancet 2013;382:1714-22

  9. Aspirin use in US secondaryprevention George MG et al, MMWR MorbMortalWklyRep 2012;61 Supp:11-8

  10. Self-reported Aspirin underuseamongUS patientswithestablishedindication Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

  11. Aspirin compliance in Europe-Latin America Zaninelliet al, PostgradMed 2009;121:44-53

  12. Aspirin compliance in Asia-Pacific Zaninelliet al, PostgradMed 2010;122:108-17

  13. Focus on post-ACS in China: the BRIG study Niuet al, Am Heart J 2009;157:709-15.e1

  14. Goalsof the Presentation • Underutilisation and poor adherence in secondary prevention of CVD • Physician and patient perceptions about Aspirin • Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

  15. Aspirin forprimaryprevention in women Ridkeret al, for the Women HealthStudyInvestigators, New Engl J Med 2005;352:1293-304

  16. Aspirin forprimaryprevention in men Physicians’ HealthStudyInvestigators, New Engl J Med 1989;321:129-35

  17. Impact on fatal/non-fatalcolorectalcancer Rothwellet al, Lancet 2010;376:1741-50

  18. Benefits vs harms Patrono et al, Eur Heart J 2013

  19. Some remainskeptical Clelandet al, Eur Heart J 2013;34:3412-8

  20. Differencesbetween US and Europe Wolffet al, AnnInternMed 2009

  21. Differencesbetween US and Europe Perket al, Eur Heart J 2012

  22. Underuse in US ambulatory care Staffordet al, PLoSMed 2005;2:e353

  23. Causesofunderuse Pignone et al, Am J PrevMed 2007;32:403-7

  24. Non-compliance vs discontinuation Herlitzet al, Am J Cardiovasc Drugs 2010;10:125-41

  25. Perceptions on Aspirin in Europe-Latin America Zaninelliet al, PostgradMed 2009;121:44-53

  26. Perceptions on Aspirin in Asia-Pacific Zaninelliet al, PostgradMed 2010;122:108-17

  27. Meanstoimprovecompliance Zaninelliet al, PostgradMed 2009;121:44-53

  28. Goalsof the Presentation • Underutilisation and poor adherence in secondary prevention of CVD • Physician and patient perceptions about Aspirin • Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

  29. Ominous impact ofaspirindiscontinuation Biondi-Zoccaiet al, Eur Heart J 2006;27:2667-74

  30. Discontinuationafterstenting Rossini et al, Am J Cardiol 2011;107:186-94

  31. Impact DAPT discontinuationafterstenting MYOCARDIAL INFARCTION CARDIAC DEATH Mehranet al, Lancet 2013;382:1714-22

  32. Discontinuation in UK primary care Rodriguez et al, BMJ 2011;343:d4094

  33. Discontinuation: thrombotic vs bleedingevents Cea Soriano et al, ThrombHaemost 2013;110:1298-304

  34. Avoidingdiscontinuationisalsocheaper Cea Soriano et al, ThrombHaemost 2013;110:1298-304

  35. Take home messages • Differentiatingbetweentype, reason, setting and timing ofunderuse and discontinuationof Aspirin iscrucial • Inadequatephysician-patientcommunication and lackofawarenessofunderlyingcardiovascularrisk and benefits are the key reasonsfor Aspirin underuse and discontinuation • Underuse and discontinuation are clearlydetrimentalforpatients, especiallyearlyafteran acute cardiovascularevent or procedure, butevenlater on

  36. Manythanksforyourattention Foranyquery: giuseppe.biondizoccai@uniroma1.it gbiondizoccai@gmail.com Forthese and otherslides:http://www.metcardio.org/slides.html

  37. Reserveslides

  38. ASPREE • ASPREE is a randomised, double-blind placebo trial of 5-year low-dose (100mg) aspirin for 5 years • It involves both males and females, 70 years and older • The study is recruiting 19,000 healthy participants through regional centres (both in urban and rural locations throughout Australia and the United States) • The trial has a number of sub-studies, which investigate the effect of aspirin on specific diseases: Biobank, ENVIS-ion, ALSOP, SNORE-ASA, ASPREE-AMD, ASPREE-Knee, and ASPREE-NEURO • Results are expected for 2018 http://www.aspree.org/AUS/aspree-content/aspree-study-details/about-aspree.aspx

  39. Aspirin: a measureofqualityof care? Quality of health care according to the US Institute of Medicine: degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with professional knowledge

  40. Aspirin discontinuation: a hot topic Biondi-Zoccaiet al, BMJ 2011;343:d3942

  41. Focus on terminology Mehranet al, Lancet 2013;382:1714-22

  42. Delayedanti-cancereffects Burnet al, Lancet 2011;378:2081-7

  43. Aspirin as key componentofpolypills Waldet al, BMJ 2003;326:1419

  44. Complianceaccordingtoindication * *with 102 (18%) reportingaspirinuse VanWormeret al, J FamPract 2012;61:525-32

  45. Some remainskeptical Sutcliffeet al, PLoS ONE 2013;8:e81970

  46. Aspirin use in US primaryprevention George MG et al, MMWR MorbMortalWklyRep 2012;61 Supp:11-8

  47. Self-reported Aspirin underuse Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

  48. Underuse in US ambulatory care Staffordet al, PLoSMed 2005;2:e353

  49. Self-reported Aspirin underuse Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

  50. Focus on post-MI in China: the BRIG study Niuet al, Am Heart J 2009;157:709-15.e1

More Related